Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis

New England Journal of Medicine

Volumn 342, Issue 12, 2000, Pages 851-859

  Lai, Hui Chuan ^a   Fitzsimmons, Stacey C ^b   Allen, David B ^a   Kosorok, Michael R ^a   Rosenstein, Beryl J ^c   Campbell, Preston W ^b   Farrell, Philip M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CYSTIC FIBROSIS FOUNDATION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISONE;

ADRENAL SUPPRESSION; ADULT; ARTICLE; BODY HEIGHT; CHILD GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GROWTH RETARDATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEROID THERAPY;

ADOLESCENT; BODY HEIGHT; BODY WEIGHT; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GROWTH; GROWTH DISORDERS; HUMANS; MALE; PREDNISONE; SEX FACTORS;

EID: 0034704799     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003233421204     Document Type: Article

References (35)

1. Lloyd-Still JD, Khaw KT, Schwachman H. Severe respiratory disease in infants with cystic fibrosis. Pediatrics 1974;53:678-82.
2. Mitchell I, Corey M, Woenne R, Krastins IR, Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. J Pediatr 1978;93:744-8.
3. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986;56:444-8.
4. Pantin CFA, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986; 41:34-8.
5. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-8.
6. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV, Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
7. Price JF, Greally P. Corticosteroid treatment in cystic fibrosis. Arch Dis Child 1993;68:719-21.
8. Berger M. Inflammation in the lung in cystic fibrosis: a vicious cycle that does more harm than good. Clin Rev Allergy 1991;9:119-42.
9. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999;115:1053-8.
10. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996;25:699-717.
11. Idem. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatr 1998;87:123-9.
12. Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715-9.
13. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93: 967-76.
14. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996;348:27-9.
15. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
16. Patel L, Clayton PE, Addison GM, Price DA, David TJ. Linear growth in prepubertal children with atopic dermatitis. Arch Dis Child 1998;79: 169-72.
17. Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word processing program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention, 1994.
18. Hamill PVV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979;32:607-29.
19. Dibley MJ, Goldsby JB, Staehling NW, Trowbridge FL. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr 1987;46:736-48.
20. Dibley MJ, Staehling NW, Nieburg P, Trowbridge FL. Interpretation of Z-score anthropometric indicators derived from the international growth reference. Am J Clin Nutr 1987;46:749-62.
21. Britton J. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 1989;298:483-7.
22. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
23. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
24. Marginal models. In: Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford, England: Clarendon Press, 1994:146-68.
25. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
26. Byard PJ. The adolescent growth spurt in children with cystic fibrosis. Ann Hum Biol 1994;21:229-40.
27. Lam CN, Arneil GC. Long-term dwarfing effects of corticosteroid treatment for childhood nephrosis. Arch Dis Child 1968;43:589-94.
28. Tanner JM. Growth as a target-seeking function: catch-up and catch-down growth in man. In: Falkner F, Tanner JM, eds. Human growth: a comprehensive treatise. 2nd ed. Vol. 1. New York: Plenum Press, 1986:167-79.
29. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosal beclomethasone dipropionate compared with theophyllinc as primary treatment for chronic, mild to moderately severe asthma in children. Pediatrics 1993;92: 64-77.
30. Heuck C, Wolthers OD, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 μg) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998;133:608-12.
31. Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993;91:1121-6.
32. Roemmich JN, Clark PA, Mai V, et al. Alterations in growth and body composition during puberty. III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. J Clin Endocrinol Metab 1998;83: 1440-7.
33. Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992;74:336-44.
34. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986; 61:1049-55.
35. Landon C, Rosenfeld RG. Short stature and pubertal delay in male adolescents with cystic fibrosis: androgen treatment. Am J Dis Child 1984; 138:388-91.